Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
5.800 USD   -4.29%
06/21EXAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/09Exagen Inc. Expands Coverage with MediNcrease
GL
06/09Exagen Inc. Expands Coverage with MediNcrease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus

05/16/2022 | 04:05pm EDT
share with twitter
share with LinkedIn
share with facebook

Exagen Inc. announced that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health, providing enhanced care to their 150,000 members. The agreement also makes AVISE® diagnostic testing available as an in-network benefit.


© S&P Capital IQ 2022
All news about EXAGEN INC.
06/21EXAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/09Exagen Inc. Expands Coverage with MediNcrease
GL
06/09Exagen Inc. Expands Coverage with MediNcrease
AQ
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
GL
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
CI
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
05/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
More news
Analyst Recommendations on EXAGEN INC.
More recommendations
Financials (USD)
Sales 2022 53,4 M - -
Net income 2022 -35,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,79x
Yield 2022 -
Capitalization 94,3 M 94,3 M -
Capi. / Sales 2022 1,77x
Capi. / Sales 2023 1,43x
Nbr of Employees 221
Free-Float 58,9%
Chart EXAGEN INC.
Duration : Period :
Exagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 5,80 $
Average target price 16,40 $
Spread / Average Target 183%
EPS Revisions
Managers and Directors
Fortunato Ron Rocca President, Chief Executive Officer & Director
Kamal Adawi Chief Financial Officer & Secretary
Brian P. Birk Chairman
Debra Jeske Zack Chief Medical Officer
Anja Kammesheidt Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EXAGEN INC.-50.13%94
CVS HEALTH CORPORATION-10.46%123 945
HCA HEALTHCARE, INC.-29.03%53 876
LABORATORY CORPORATION OF AMERICA HOLDINGS-22.80%22 485
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY21.44%18 281
QUEST DIAGNOSTICS-20.57%16 467